DE60116483D1 - Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze - Google Patents

Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze

Info

Publication number
DE60116483D1
DE60116483D1 DE60116483T DE60116483T DE60116483D1 DE 60116483 D1 DE60116483 D1 DE 60116483D1 DE 60116483 T DE60116483 T DE 60116483T DE 60116483 T DE60116483 T DE 60116483T DE 60116483 D1 DE60116483 D1 DE 60116483D1
Authority
DE
Germany
Prior art keywords
salts
pharmaceutical composition
bisphosphonic acids
applications containing
gel pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60116483T
Other languages
English (en)
Other versions
DE60116483T2 (de
Inventor
Rainer Bader
Petra Bastian
Achim Goepferich
Wolfgang Roedel
Gerhard Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to DE60116483T priority Critical patent/DE60116483T2/de
Publication of DE60116483D1 publication Critical patent/DE60116483D1/de
Application granted granted Critical
Publication of DE60116483T2 publication Critical patent/DE60116483T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
DE60116483T 2000-05-05 2001-04-23 Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze Expired - Lifetime DE60116483T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE60116483T DE60116483T2 (de) 2000-05-05 2001-04-23 Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10021917 2000-05-05
DE10021917 2000-05-05
DE60116483T DE60116483T2 (de) 2000-05-05 2001-04-23 Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze
PCT/EP2001/004550 WO2001085217A1 (en) 2000-05-05 2001-04-23 Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts

Publications (2)

Publication Number Publication Date
DE60116483D1 true DE60116483D1 (de) 2006-03-30
DE60116483T2 DE60116483T2 (de) 2006-09-07

Family

ID=7640900

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60116483T Expired - Lifetime DE60116483T2 (de) 2000-05-05 2001-04-23 Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze

Country Status (16)

Country Link
US (1) US6676970B2 (de)
EP (1) EP1284754B1 (de)
JP (1) JP3923800B2 (de)
KR (1) KR100492110B1 (de)
CN (1) CN1180846C (de)
AR (2) AR033671A1 (de)
AT (1) ATE314862T1 (de)
AU (1) AU778431B2 (de)
BR (1) BR0110618A (de)
CA (1) CA2407747C (de)
DE (1) DE60116483T2 (de)
DK (1) DK1284754T3 (de)
ES (1) ES2254410T3 (de)
MX (1) MXPA02010740A (de)
WO (1) WO2001085217A1 (de)
ZA (1) ZA200208499B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438208A1 (en) * 2001-02-07 2002-08-15 Durect Corporation Devices and methods for management of bone density
US7875597B2 (en) * 2002-07-24 2011-01-25 New York University Treatment of spinal mechanical pain
CN100364544C (zh) * 2004-07-21 2008-01-30 上海第二医科大学附属瑞金医院 一种携带二氯亚甲基二膦酸的明胶微粒及制备方法
JP4559431B2 (ja) * 2004-08-23 2010-10-06 テバ ファーマシューティカル インダストリーズ リミティド 固体及び結晶イバンドロネートナトリウム及びその調製方法
US7294195B2 (en) * 2005-08-08 2007-11-13 Wacker Chemical Corporation Water repellant gypsum compositions
ITMI20052515A1 (it) * 2005-12-29 2007-06-30 Abiogen Pharma Spa Formulazione farmaceutica per il trattamento della osteoartrite
WO2008059060A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Liquid pharmaceutical compositions comprising a bisphosphonate compound
EP1923049A1 (de) * 2006-11-17 2008-05-21 Besins Healthcare Pharmazeutische Zusammensetzungen mit einer Bisphosphonatverbindung
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
EP1992364A1 (de) * 2007-05-16 2008-11-19 Biosuma S.r.l. Phosphierte oder bisphosphonierte und optional vernetzte Derivate carboxylierter Polysaccharide sowie ihre Herstellung und ihre biomedizinischen Verwendungen
US20090311237A1 (en) * 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
WO2010111627A1 (en) * 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
NO2459176T3 (de) 2009-07-31 2018-02-24
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102000094B (zh) * 2010-09-27 2013-03-27 天津南开允公医药科技有限公司 一种含有伊班膦酸的药物组合物及制备工艺
US20120089118A1 (en) * 2010-10-08 2012-04-12 A Nevada Corporation Delivery of bisphosphonates by microinjection systems
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
GB201412236D0 (en) * 2014-07-09 2014-08-20 Univ Nottingham Method of producing and using alginate hydrogels
EP3189852B1 (de) * 2014-09-03 2021-04-07 Nitto Denko Corporation Bisphosphonathaltige pharmazeutische impfstoffzusammensetzung für humorale immunität
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
IT201800009444A1 (it) 2018-10-15 2020-04-15 Fidia Farm Spa Coniugati tra acido ialuronico e amminobisfosfonati e loro impiego terapeutico

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE61111C (de) B. WINKLER in Berka a. Werrä Verfahren zur Herstellung von Knöpfen ohne Fadenbefestigung
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922077A (en) 1989-01-31 1990-05-01 Raytheon Company Method of laser marking metal packages
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
DE4223940A1 (de) * 1992-07-21 1994-01-27 Boehringer Mannheim Gmbh Neue acyclische Amidingruppen-haltige Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4228552A1 (de) * 1992-08-27 1994-03-03 Boehringer Mannheim Gmbh Diphosphonsäuren und deren Salze enthaltende Arzneimittel
DE4244422A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Schwerlösliche Zink- und Magnesiumsalze von 1,1-Bisphosphonsäuren, ihre Herstellung und Verwendung als Arzneimittel
DE4244423A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Wasserlösliche Calciumsalze der 1-Hydroxy-3-(methylpentylamino)propan-1,1-bisphosphonsäure, ihre Herstellung und Verwendung als Arzneimittel
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation

Also Published As

Publication number Publication date
AU5631701A (en) 2001-11-20
EP1284754B1 (de) 2006-01-04
JP2003532689A (ja) 2003-11-05
CA2407747A1 (en) 2001-11-15
CN1180846C (zh) 2004-12-22
AR055407A2 (es) 2007-08-22
US20010053388A1 (en) 2001-12-20
CA2407747C (en) 2008-03-11
AR033671A1 (es) 2004-01-07
DK1284754T3 (da) 2006-05-01
KR100492110B1 (ko) 2005-06-02
CN1427727A (zh) 2003-07-02
WO2001085217A1 (en) 2001-11-15
ES2254410T3 (es) 2006-06-16
EP1284754A1 (de) 2003-02-26
ZA200208499B (en) 2004-02-26
JP3923800B2 (ja) 2007-06-06
US6676970B2 (en) 2004-01-13
DE60116483T2 (de) 2006-09-07
ATE314862T1 (de) 2006-02-15
KR20030009470A (ko) 2003-01-29
MXPA02010740A (es) 2003-03-10
AU778431B2 (en) 2004-12-02
BR0110618A (pt) 2003-04-29

Similar Documents

Publication Publication Date Title
DE60116483D1 (de) Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze
BR0207726A (pt) Sais farmacêuticos
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
SI1687019T1 (en) PROPILED GLIKO-CONTAINING PEPTIDAL FORMULATIONS OPTIMAL FOR MANUFACTURING AND FOR USE IN INJECTION DEVICES
BR0013823A (pt) Formas de apresentação farmacêuticas de tramadol e seu processo de fabricação
AR018440A1 (es) Composicion de compuestos de boroprolina ciclico, metodo para la fabricacion de dicha composicion farmaceutica, metodo para estimular la activacion o laproliferacion de linfocitos o celulas hematopoyeticas humanas, y uso de dichos compuestos para preparar un medicamento util para estimular la activa
DE60030263D1 (de) Neue phosphor enthaltende medikamentenvorläuferverbindungen
BR0111126A (pt) Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos
ATE419842T1 (de) Abgabevehikel mit nanoteilchen
PE20050438A1 (es) Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0407430A (pt) Sal do ácido benzenossulfÈnico com clopidogrel, processos para preparação do mesmo, e para purificação de clopidogrel, uso de um sal, formulação farmacêutica, partìculas de substância ativa, uso de partìculas de substância ativa, e, processo para preparação de partìculas de substância ativa
ECSP066477A (es) Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo
CY1108401T1 (el) Παραγωγα πυρρολοϊμιδαζολης, η παρασκευη τους, φαρμακευτικες συνθεσεις που τα περιεχουν και η χρηση τους ως νοοτροπικων παραγοντων
DE69605298T2 (de) Herstellung von formulierungen zur arzneiverabreichung mittels elektrotransport
BR0110892A (pt) Forma de administração farmacêutica para peptìdios, processos para preparação e uso dos mesmos
ATE539761T1 (de) Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції
CL2008001332A1 (es) Uso de temozolomida para preparar un medicamento util para el tratamiento de un desorden proliferativo.
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
ATE362756T1 (de) Schmerzfreie injektions-zubereitungen von 2- arylpropionsäuresalzen
EA201390181A1 (ru) Несущий корпус для лекарственного средства и способ его изготовления
BR0307009A (pt) Sais estáveis de ácido o-acetilsalicìlico com aminoácidos básicos ii
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav

Legal Events

Date Code Title Description
8364 No opposition during term of opposition